BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS

Posted on by

Meeting Provided a Clear Path for Planned Phase 3b Trial NEW YORK, Dec. 7, 2023 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the completion of a productive meeting with…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.